المؤلفون: Labbouz, Sofia, Khan, Sidra, Gohara, Mona, Lucas, Jennifer, Sarkar, Rashmi, Murrell, Dedee F., Dodiuk-Gad, Roni P.

المصدر: International Journal of Women’s Dermatology, Vol 10, Issue 1, e125.

مصطلحات موضوعية: WA 309 Women's health, WR 20 Research (General)

وصف الملف: text

العلاقة: https://archive.lstmed.ac.uk/23919/1/meeting_report__women_s_dermatology_society_forum.4.pdfTest; Labbouz, Sofia, Khan, Sidra, Gohara, Mona, Lucas, Jennifer, Sarkar, Rashmi, Murrell, Dedee F. and Dodiuk-Gad, Roni P. (2024) 'Meeting report: Women’s Dermatology Society Forum at the 25th World Congress of Dermatology, Singapore, 2023'. International Journal of Women’s Dermatology, Vol 10, Issue 1, e125.

الإتاحة: https://doi.org/10.1097/jw9.0000000000000125Test
https://archive.lstmed.ac.uk/23919Test/
https://archive.lstmed.ac.uk/23919/1/meeting_report__women_s_dermatology_society_forum.4.pdfTest

المؤلفون: Reiter, Ofer, Leshem, Avner, Alexander-Shani, Rivka, Brandwein, Michael, Cohen, Yotam, Yeshurun, Algit, Ziv, Michael, Elinav, Eran, Hodak, Emmilia, Dodiuk-Gad, Roni P.

المصدر: Dermatology ; volume 240, issue 3, page 443-452 ; ISSN 1018-8665 1421-9832

الوصف: Introduction: Darier disease is a rare inherited disease with dominant skin manifestations including keratotic papules and plaques on sebaceous and flexural areas. Secondary infection of skin lesions is common, and Staphylococcus aureus commonly colonizes these lesions. The aim of the study was to characterize the bacterial microbiome of cutaneous Darier lesions compared to normal-looking skin and disease severity. Methods: All patients with a history of Darier followed up at Emek Medical Center were invited to participate in the study. Patients that did not use antibiotics in the past month and signed informed consent had four skin sites sampled with swabs: scalp, chest, axilla, and palm. All samples were analyzed for bacterial microbiome using 16S rDNA sequencing. Results: Two hundred and eighty microbiome samples obtained from lesional and non-lesional skin of the scalp, chest, axilla, and palm of 42 Darier patients were included in the analysis. The most abundant bacterial genera across all skin sites were Propionibacterium, Corynebacterium, Paracoccus, Micrococcus, and Anaerococcus. Scalp and chest lesions featured a distinct microbiome configuration that was mainly driven by an overabundance of Staphylococci species. Patients with more severe disease exhibited microbiome alterations in the chest, axilla, and palm compared with patients with only mild disease, driven by Peptoniphilus and Moryella genera in scalp and palmar lesions, respectively. Conclusion: Staphylococci were significantly associated with Darier lesions and drove Darier-associated dysbiosis. Severity of the disease was associated with two other bacterial genera. Whether these associations also hold a causative role and may serve as a therapeutic target remains to be determined and requires further investigation.

الإتاحة: https://doi.org/10.1159/000537714Test
https://karger.com/drm/article-pdf/240/3/443/4240512/000537714.pdfTest

المؤلفون: Strahan, Alexis G, Davies, Olivia M T, Fernández, Lucía T, Inena Gaylord, Inena Wa, Mekonnen, Yared Getachew, Grijsen, Marlous L, Ollague, Jose E, Sabushimike, Doriane, Polo Silveira, Luisa, Maurer, Toby, Dodiuk-Gad, Roni P, Singal, Archana, Lim, Henry W, Bhose, Arpita, Lubov, Janet E, Jain, Shivani, Zehtab, Morvarid, Allison, Tom, Guerin, Maud, Enbiale, Wendemagegn, Rehmus, Wingfield, Wanat, Karolyn A, Fuller, L Claire, Bailey, Elizabeth, Freeman, Esther E

المصدر: British Journal of Dermatology ; ISSN 0007-0963 1365-2133

الوصف: Lack of access to dermatologic care is a global health crisis. Providing intentional mentorship to emerging leaders in low and middle income countries is foundational to increasing access to care.The GLODERM mentorship program is a first of its kind program created to support changemakers in global health dermatology in enhancement of leadership skills.

الإتاحة: https://doi.org/10.1093/bjd/ljae164Test

المؤلفون: Merola, Joseph F, Chiou, Albert S, During, Emmanuel, Costanzo, Antonio, Foley, Peter, Alfalasi, Amani, Gogate, Shaila, Pinter, Andreas, Dodiuk-Gad, Roni, Simon, Dagmar, Tauber, Marie, Weller, Richard, Pereyra-Rodriguez, Jose-Juan, Ardeleanu, Marius, Wu, Jiangming, Ozturk, Zafer E

المصدر: Merola, Joseph F; Chiou, Albert S; During, Emmanuel; Costanzo, Antonio; Foley, Peter; Alfalasi, Amani; Gogate, Shaila; Pinter, Andreas; Dodiuk-Gad, Roni; Simon, Dagmar; Tauber, Marie; Weller, Richard; Pereyra-Rodriguez, Jose-Juan; Ardeleanu, Marius; Wu, Jiangming; Ozturk, Zafer E (2023). Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study. The British journal of dermatology, 189(6), pp. 685-694. Wiley 10.1093/bjd/ljad284

مصطلحات موضوعية: 610 Medicine & health

الوصف: BACKGROUND Sleep disturbance is a prominent symptom of atopic dermatitis (AD) and can result in insomnia, daytime fatigue, drowsiness, reduced productivity and impaired quality of life (QoL). OBJECTIVES The Dupilumab Effect on Sleep in AD Patients (DUPISTAD) phase IV randomized double-blinded placebo-controlled study evaluated the impact of dupilumab treatment on sleep and other patient- and physician-reported outcomes. METHODS Adults with moderate-to-severe AD were randomized 2 : 1 to dupilumab 300 mg once every 2 weeks (q2w) or placebo for 12 weeks; concomitant topical corticosteroids were permitted. Patients subsequently entered an open-label phase and received dupilumab 300 mg q2w for a further 12 weeks. The primary endpoint was the percentage change in sleep quality from baseline to week 12, assessed using a novel numeric rating scale (NRS). Secondary and exploratory endpoints included percentage change in peak pruritus NRS (PP NRS), change in SCORing Atopic Dermatitis (SCORAD), SCORAD sleep visual analogue scale (VAS), Eczema Area and Severity Index, Patient-Reported Outcomes Measurement Information System (PROMIS) sleep-related impairment T-score and the Epworth Sleepiness Scale. Sleep diary and wrist actigraphy measurements were recorded throughout the study. RESULTS In total, 127 patients received dupilumab and 61 patients received placebo. Demographic and baseline disease characteristics were balanced between groups. Sleep quality NRS significantly improved in patients treated with dupilumab by week 12 vs. placebo [least squares mean of the difference (LSMD) -15.5%, P < 0.001]. PP NRS (LSMD -27.9%, P < 0.001), SCORAD (LSMD -15.1, P < 0.001), SCORAD sleep VAS (LSMD -2.1, P < 0.001) and PROMIS T-score (LSMD -3.6, P < 0.001) were also significantly improved at week 12 with dupilumab vs. placebo. The overall percentage of patients reporting treatment-emergent adverse events was lower in the dupilumab group (56.7%) than in the placebo group (67.2%). CONCLUSIONS Dupilumab significantly ...

وصف الملف: application/pdf

العلاقة: https://boris.unibe.ch/189990Test/

الإتاحة: https://doi.org/10.1093/bjd/ljad284Test
https://boris.unibe.ch/189990/1/ljad284.pdfTest
https://boris.unibe.ch/189990Test/

المؤلفون: Samuelov, Liat, Shemer, Avner, Greenberger, Shoshana, Ziv, Inbal, Friedman, Doron, Yacoby‐Zeevi, Oron, Dodiuk‐Gad, Roni, Ramot, Yuval, Murad, Sari, Sprecher, Eli

المصدر: Skin Health and Disease ; volume 3, issue 6 ; ISSN 2690-442X 2690-442X

الوصف: Background Atopic dermatitis (AD) is one of the most common inflammatory skin diseases. It is associated with significant itch and impaired quality of life. Systemic treatments are efficient but associated with side effects. Novel topical treatments with a favourable safety profile are needed. SNG100 is a novel composition of hydrocortisone 1% in a cream base comprising sulphated polysaccharide (SPS; extracted from in‐house cultivated Porphyridium Cruentum unicellular algae), a well‐known hydrating, moisturising and a skin barrier repairing agent. Objectives To assess the safety, usability and efficacy of SNG100 cream in patients aged ≥6 years with moderate AD. Methods In this proof of concept phase I, double‐blind, randomised trial, participants received one of three treatments for 14 days: SNG100 twice daily (BID), hydrocortisone 1% BID or mometasone furoate once daily (QD). The primary endpoint was the safety and tolerability of SNG100 cream compared to hydrocortisone 1% and mometasone furoate. The secondary endpoint was the subject's usability of SNG100. Exploratory efficacy endpoints included percent change from baseline in SCOring AD (SCORAD), Eczema Area and Severity Index, Patient‐Oriented Eczema Measure, Dermatology Life Quality Index, pruritus Numerical Rating Score (NRS), peak pruritus‐NRS and Investigator's Global Assessment. Subjects were also followed up without any treatment for additional 14 days. Results Overall, 66 participants were screened, and 60 patients were randomised. SNG100 demonstrated a high safety profile, similar to marketed products hydrocortisone 1% and mometasone furoate 0.1%, with no unanticipated drug safety related events. SNG100 and mometasone furoate 0.1% cream achieved almost similar and statistically significant greater percentage reductions from baseline in SCORAD as compared to hydrocortisone 1% cream. SNG100 demonstrated significant improvement in NRS as compared to hydrocortisone 1% cream. Remarkably, SNG100 led to a lasting effect with only 29.4% of subjects ...

الإتاحة: https://doi.org/10.1002/ski2.293Test

المؤلفون: Sowlati, Mehdi, Morariu, Silviu-Horia, Orzan, Olguta, Veraldi, Stefano, Dodiuk-Gad, Roni P., Orasan, Remus I., Gainaru, Cristian

المساهمون: Novintethical Pharma SA

المصدر: Dermatology and Therapy ; volume 13, issue 11, page 2669-2679 ; ISSN 2193-8210 2190-9172

مصطلحات موضوعية: Dermatology

الإتاحة: https://doi.org/10.1007/s13555-023-01035-6Test

المؤلفون: Marks, Madeline E., Botta, Ramya Krishna, Abe, Riichiro, Beachkofsky, Thomas M., Boothman, Isabelle, Carleton, Bruce C., Chung, Wen-Hung, Cibotti, Ricardo R., Dodiuk-Gad, Roni P., Grimstein, Christian, Hasegawa, Akito, Hoofnagle, Jay H., Hung, Shuen-Iu, Kaffenberger, Benjamin, Kroshinsky, Daniela, Lehloenya, Rannakoe J., Martin-Pozo, Michelle, Micheletti, Robert G., Mockenhaupt, Maja, Nagao, Keisuke, Pakala, Suman, Palubinsky, Amy, Pasieka, Helena B., Peter, Jonathan, Pirmohamed, Munir, Reyes, Melissa, Saeed, Hajirah N., Shupp, Jeffery, Sukasem, Chonlaphat, Syu, Jhih Yu, Ueta, Mayumi, Zhou, Li, Chang, Wan-Chun, Becker, Patrice, Bellon, Teresa, Bonnet, Kemberlee, Cavalleri, Gianpiero, Chodosh, James, Dewan, Anna K., Dominguez, Arturo, Dong, Xinzhong, Ezhkova, Elena, Fuchs, Esther, Goldman, Jennifer, Himed, Sonia, Mallal, Simon, Markova, Alina, McCawley, Kerry, Norton, Allison E., Ostrov, David

المصدر: Frontiers in Medicine ; volume 10 ; ISSN 2296-858X

مصطلحات موضوعية: General Medicine

الوصف: Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) is a predominantly drug-induced disease, with a mortality rate of 15–20%, that engages the expertise of multiple disciplines: dermatology, allergy, immunology, clinical pharmacology, burn surgery, ophthalmology, urogynecology, and psychiatry. SJS/TEN has an incidence of 1–5/million persons per year in the United States, with even higher rates globally. One of the challenges of SJS/TEN has been developing the research infrastructure and coordination to answer questions capable of transforming clinical care and leading to improved patient outcomes. SJS/TEN 2021, the third research meeting of its kind, was held as a virtual meeting on August 28–29, 2021. The meeting brought together 428 international scientists, in addition to a community of 140 SJS/TEN survivors and family members. The goal of the meeting was to brainstorm strategies to support the continued growth of an international SJS/TEN research network, bridging science and the community. The community workshop section of the meeting focused on eight primary themes: mental health, eye care, SJS/TEN in children, non-drug induced SJS/TEN, long-term health complications, new advances in mechanisms and basic science, managing long-term scarring, considerations for skin of color, and COVID-19 vaccines. The meeting featured several important updates and identified areas of unmet research and clinical need that will be highlighted in this white paper.

الإتاحة: https://doi.org/10.3389/fmed.2023.1213889Test

المؤلفون: Hama, Natsumi, Sunaga, Yuma, Ochiai, Hirotaka, Kokaze, Akatsuki, Watanabe, Hideaki, Kurosawa, Michiko, Azukizawa, Hiroaki, Asada, Hideo, Watanabe, Yuko, Yamaguchi, Yukie, Aihara, Michiko, Mizukawa, Yoshiko, Ohyama, Manabu, Hashizume, Hideo, Nakajima, Saeko, Nomura, Takashi, Kabashima, Kenji, Tohyama, Mikiko, Hasegawa, Akito, Takahashi, Hayato, Mieno, Hiroki, Ueta, Mayumi, Sotozono, Chie, Niihara, Hiroyuki, Morita, Eishin, Brüggen, Marie-Charlotte, Feingold, Iris Motro, Jeschke, Marc G., Dodiuk-Gad, Roni P., Oppel, Eva Maria, French, Lars E., Chen, Wei-Ti, Chung, Wen-Hung, Chu, Chia-Yu, Kang, Hye-Ryun, Ingen-Housz-Oro, Saskia, Nakamura, Kazutoshi, Sueki, Hirohiko, Abe, Riichiro

المساهمون: Ministry of Health, Labour and Welfare, Japan Organisation of Occupational Health and Safety, Japan Society for the Promotion of Science

المصدر: The Journal of Allergy and Clinical Immunology: In Practice ; volume 11, issue 10, page 3161-3168.e2 ; ISSN 2213-2198

مصطلحات موضوعية: Immunology and Allergy

الإتاحة: https://doi.org/10.1016/j.jaip.2023.07.001Test
https://api.elsevier.com/content/article/PII:S2213219823007298?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2213219823007298?httpAccept=text/plainTest

المؤلفون: Maspero, Jorge, De Paula Motta Rubini, Norma, Zhang, Jianzhong, Sanclemente, Gloria, Amador, Julio Roberto, El Sayed, Mahira Hamdy, Chan Wai Ming, Alson, Dodiuk-Gad, Roni P., Hamadah, Issam, Thevarajah, Suganthi, Rincón-Perez, Catalina, Fedenko, Elena, Yew, Yik Weng, Tang, Mark B.Y., Chu, Chia-Yu, Kulthanan, Kanokvalai, Kucuk, Ozlem Su, Al-Hammadi, Anwar, Brignoli, Lysel, Tsankova, Angelina, El-Samad, Sarah, Neves, Jose Eduardo, Eckert, Laurent

المصدر: World Allergy Organization Journal ; volume 16, issue 3, page 100724 ; ISSN 1939-4551

مصطلحات موضوعية: Immunology and Allergy, Immunology, Pulmonary and Respiratory Medicine

الإتاحة: https://doi.org/10.1016/j.waojou.2022.100724Test
https://api.elsevier.com/content/article/PII:S1939455122001004?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1939455122001004?httpAccept=text/plainTest

المؤلفون: Atzmony, Lihi, Zagairy, Fadia, Mawassi, Banan, Shehade, Majd, Tatour, Yasmin, Danial-Farran, Nada, Khayat, Morad, Warrour, Nassim, Dodiuk-Gad, Roni, Cohen-Barak, Eran

المصدر: JAMA Dermatology; May2024, Vol. 160 Issue 5, p518-524, 7p